ATXS
Price
$5.28
Change
+$0.32 (+6.45%)
Updated
Jun 4 closing price
Capitalization
297.97M
67 days until earnings call
DNLI
Price
$14.42
Change
+$0.49 (+3.52%)
Updated
Jun 4 closing price
Capitalization
2.09B
56 days until earnings call
Interact to see
Advertisement

ATXS vs DNLI

Header iconATXS vs DNLI Comparison
Open Charts ATXS vs DNLIBanner chart's image
Astria Therapeutics
Price$5.28
Change+$0.32 (+6.45%)
Volume$293.15K
Capitalization297.97M
Denali Therapeutics
Price$14.42
Change+$0.49 (+3.52%)
Volume$2.08M
Capitalization2.09B
ATXS vs DNLI Comparison Chart
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. DNLI commentary
Jun 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Buy and DNLI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 05, 2025
Stock price -- (ATXS: $5.28 vs. DNLI: $14.42)
Brand notoriety: ATXS and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 56% vs. DNLI: 133%
Market capitalization -- ATXS: $297.97M vs. DNLI: $2.09B
ATXS [@Biotechnology] is valued at $297.97M. DNLI’s [@Biotechnology] market capitalization is $2.09B. The market cap for tickers in the [@Biotechnology] industry ranges from $318.09B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, DNLI is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 5 TA indicator(s) are bullish while DNLI’s TA Score has 4 bullish TA indicator(s).

  • ATXS’s TA Score: 5 bullish, 4 bearish.
  • DNLI’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ATXS is a better buy in the short-term than DNLI.

Price Growth

ATXS (@Biotechnology) experienced а +29.10% price change this week, while DNLI (@Biotechnology) price change was +10.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.56%. For the same industry, the average monthly price growth was +5.22%, and the average quarterly price growth was -1.09%.

Reported Earning Dates

ATXS is expected to report earnings on Aug 11, 2025.

DNLI is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+6.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.1B) has a higher market cap than ATXS($298M). DNLI YTD gains are higher at: -29.244 vs. ATXS (-40.940). ATXS has higher annual earnings (EBITDA): -111.56M vs. DNLI (-505.16M). DNLI has more cash in the bank: 818M vs. ATXS (328M). ATXS has less debt than DNLI: ATXS (5.35M) vs DNLI (48.6M). ATXS (0) and DNLI (0) have equivalent revenues.
ATXSDNLIATXS / DNLI
Capitalization298M2.1B14%
EBITDA-111.56M-505.16M22%
Gain YTD-40.940-29.244140%
P/E RatioN/AN/A-
Revenue00-
Total Cash328M818M40%
Total Debt5.35M48.6M11%
FUNDAMENTALS RATINGS
ATXS vs DNLI: Fundamental Ratings
ATXS
DNLI
OUTLOOK RATING
1..100
1960
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
93
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9440
PRICE GROWTH RATING
1..100
8888
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATXS's Valuation (58) in the Biotechnology industry is somewhat better than the same rating for DNLI (93). This means that ATXS’s stock grew somewhat faster than DNLI’s over the last 12 months.

ATXS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DNLI (100). This means that ATXS’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (40) in the Biotechnology industry is somewhat better than the same rating for ATXS (94). This means that DNLI’s stock grew somewhat faster than ATXS’s over the last 12 months.

DNLI's Price Growth Rating (88) in the Biotechnology industry is in the same range as ATXS (88). This means that DNLI’s stock grew similarly to ATXS’s over the last 12 months.

DNLI's P/E Growth Rating (98) in the Biotechnology industry is in the same range as ATXS (100). This means that DNLI’s stock grew similarly to ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSDNLI
RSI
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 3 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
81%
Momentum
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
77%
MACD
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 17 days ago
78%
Declines
ODDS (%)
Bearish Trend 28 days ago
90%
Bearish Trend 9 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
88%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OAZBX36.370.05
+0.14%
Oakmark Equity and Income R6
SBICX9.57N/A
N/A
ClearBridge International Value C
PPYAX8.34N/A
N/A
PIMCO RAE International A
CSCZX48.84N/A
N/A
Columbia Small Cap Value I Inst
HLPPX9.87N/A
N/A
LDR Real Estate Value Opportunity P

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with TRDA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+6.45%
TRDA - ATXS
53%
Loosely correlated
-3.76%
KYMR - ATXS
53%
Loosely correlated
+1.56%
CRNX - ATXS
53%
Loosely correlated
+0.78%
XENE - ATXS
51%
Loosely correlated
-0.85%
DNLI - ATXS
51%
Loosely correlated
+3.52%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with NRIX. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+3.52%
NRIX - DNLI
56%
Loosely correlated
+0.66%
BEAM - DNLI
55%
Loosely correlated
+1.60%
ARWR - DNLI
54%
Loosely correlated
+0.78%
RGNX - DNLI
54%
Loosely correlated
-0.49%
DAWN - DNLI
52%
Loosely correlated
-0.72%
More